Elasmogen Ltd

Elasmogen is a biotechnology startup founded in 2016, with a mission to improve outcomes and quality of life for individuals battling difficult-to-treat diseases. The company's focus lies in developing multi-functional therapeutic biologics utilizing its proprietary soloMER technology. This includes the creation of first-in-class drug conjugates (SDC) and bi-specific products for treating autoimmune diseases. Moreover, Elasmogen's pipeline also encompasses soloMER-targeted RadioPharmaceutical Therapies (RPT) tailored for solid tumor cancers in the oncology domain. The company recently secured a notable £8.00M Venture Round investment on 18 May 2022. This funding round saw participation from various key investors including Scottish Enterprise, Scottish National Investment Bank, and Business Growth Fund, signifying noteworthy support from both public and private funding entities. Elasmogen's compelling focus on leveraging its proprietary technology to address challenging medical conditions, coupled with the recent substantial investment, positions the company as a promising player in the biotech landscape. With a keen eye on research and development, the company appears poised to make significant strides in the therapeutic biologics space, thereby attracting attention from potential venture capital partners seeking to contribute to impactful and innovative healthcare solutions.